Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 11, 2022
Share
Easywell Biomedicals, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 34.92 million compared to TWD 46.53 million a year ago. Net loss was TWD 37.33 million compared to TWD 61.44 million a year ago. Basic loss per share from continuing operations was TWD 0.3286 compared to TWD 0.6143 a year ago. Basic loss per share was TWD 0.3286 compared to TWD 0.6143 a year ago.
For the six months, sales was TWD 69.99 million compared to TWD 118.16 million a year ago. Net loss was TWD 89.51 million compared to TWD 56.39 million a year ago. Basic loss per share from continuing operations was TWD 0.7857 compared to TWD 0.5714 a year ago. Basic loss per share was TWD 0.7857 compared to TWD 0.5714 a year ago.
Easywell Biomedicals Inc. is a Taiwan-based company principally engaged in the research, development, production and sale of raw materials and temperature measurement products. The raw materials are applied in the manufacture of medicament for the treatment of epilepsy, pain and fever, antihypertensive and diuretic, skeletal muscle relaxants, among others. The Company's diagnostic devices include ear thermometers and digital clinical thermometers. The Company distributes its products mainly in Taiwan, the Americas and Europe.
EASYWELL BIOMEDICALS, INC. 